Skip to main content
. Author manuscript; available in PMC: 2021 Jul 28.
Published in final edited form as: Hepatology. 2021 Jun 15;74(1):281–295. doi: 10.1002/hep.31652

Fig. 4. Inflammatory bowel disease and bile acids in PSC.

Fig. 4.

(A) Principle components analysis (PCA) of individual BA concentrations in PSC patients with No IBD, ulcerative colitis (UC), Crohn’s Disease (CD) or indeterminate IBD (Ind IBD); (B) Plasma BA composition by BA family type in PSC patients by IBD group; (C) Comparison of concentration (μmol/L) and conjugated fraction of total bile acids (TBA) between PSC patients with No IBD and PSC patients with Ind IBD, CD or UC; (D) Comparison of CA:CDCA and CA:DCA ratios between (1) Controls and PSC patients with No IBD and (2) PSC patients with No IBD and PSC patients with Ind IBD, CD or UC. Significance level: *p<0.05, **p≤0.001; Kruskal-Wallis rank sum test. Non-significant comparisons (p≥0.05) are not highlighted in this figure.